Managing Anorexia-Cachexia Syndrome in Hospice Care

Introduction

‍
Anorexia–cachexia syndrome (ACS) is a complex metabolic condition commonly encountered in hospice and palliative care. It is characterized by decreased appetite (anorexia), unintended weight loss, muscle wasting, and systemic inflammation. ACS is particularly prevalent in advanced cancer but is also seen in end-stage heart failure, chronic obstructive pulmonary disease (COPD), renal disease, and neurodegenerative conditions. Its presence often signals disease progression and can significantly impact quality of life for both patients and their families.

Pathophysiology

‍
Unlike simple starvation, ACS is driven by a multifactorial process involving inflammatory cytokines (e.g., TNF-α, IL-1, IL-6), hormonal dysregulation, and altered metabolism. These changes lead to increased resting energy expenditure, impaired protein synthesis, and accelerated muscle breakdown. Importantly, nutritional supplementation alone does not reverse cachexia, distinguishing it from malnutrition.

Clinical Features and Assessment

‍
Patients with ACS may present with:

• Reduced appetite and early satiety
• Progressive weight loss and muscle wasting
• Fatigue and decreased functional status
• Altered taste and smell

Assessment should focus on identifying reversible contributors, such as:

• Pain
• Constipation
• Nausea/vomiting
• Depression or anxiety
• Medication side effects

Validated tools such as the Edmonton Symptom Assessment System (ESAS) can help quantify symptom burden and guide management.

Management Strategies

‍
Management of ACS in hospice care emphasizes comfort, quality of life, and alignment with patient goals rather than aggressive reversal of weight loss.

1. ‍Non-Pharmacologic Approaches:
   • Encourage small, frequent, high-calorie meals
   • Focus on patient food preferences rather than strict dietary rules
   • Provide social and environmental support during meals
   • Educating families that reduced intake is a natural part of the dying process
     ‍
2. ‍Pharmacologic Interventions: Pharmacologic therapy may be appropriate for select patients, particularly when appetite loss is distressing.
   • ‍Dexamethasone:
     Provides short-term appetite stimulation and improved sense of well-being. Benefits are often transient (weeks), but long-term use is less effective and limited by side effects such as hyperglycemia, myopathy, and immunosuppression. Additionally, it is a very cost-effective option with a monthly cost of less than $30.
   • Megestrol acetate:
     Can improve appetite and weight gain (primarily fat mass), though risks include thromboembolism, edema, and adrenal suppression. Typically, second line to dexamethasone or corticosteroids.
   • Olanzapine:
     Recommended agent for cancer-related anorexia-cachexia syndrome. Studies have demonstrated significant improvements in appetite and weight gain, with a limited side effect profile. Additionally, this is a very cost-effective option (less than $30 per month) and has an orally disintegrating formulation.
   • Dronabinol:
     Synthetic cannabinoid analog, primarily used for ACS secondary to HIV/AIDS. May improve appetite and mood in some patients, though evidence is mixed and effects are generally modest. Typically cost prohibitive for many hospice organizations, with a monthly cost of more than $200.
   • Mirtazapine:
     Useful when depression, insomnia, or nausea coexist; may also promote appetite. However, controlled trials show conflicting results in appetite improvement or weight gain.
     ‍
3. Interventions to Avoid
   • Enteral or parenteral nutrition is generally not recommended in advanced hospice patients, as it does not improve survival or quality of life and may increase discomfort.
   • Aggressive nutritional goals can create emotional distress for families and should be reframed toward comfort-focused care.

Communication and Family Support

‍
One of the most critical aspects of managing ACS is communication. Families often equate food intake with care and survival, leading to distress when patients eat less. Clinicians should:

• Normalize decreased appetite as part of disease progression
• Reassure that patients are not "starving" in the traditional sense
• Emphasize comfort over caloric intake
• Encourage meaningful, non-food-based interactions

Conclusion

‍
Anorexia–cachexia syndrome is a hallmark of advanced illness that requires a compassionate, patient-centered approach. Effective management focuses on symptom relief, minimizing burdensome interventions, and supporting both patients and families through education and shared decision-making. Recognizing ACS as a natural component of the dying process allows clinicians to prioritize dignity and comfort at the end of life.
‍

References:

Argilés, J. M., Busquets, S., Stemmler, B., & López-Soriano, F. J. (2014). Cancer cachexia: Understanding the molecular basis. Nature Reviews Cancer, 14(11), 754–762. https://doi.org/10.1038/nrc3829

Davis, M. P., & Dickerson, D. (2000). Cachexia and anorexia: Cancer’s covert killer. Supportive Care in Cancer, 8(3), 180–187. https://doi.org/10.1007/s005200050284

Del Fabbro, E., Dev, R., Hui, D., Palmer, L., Bruera, E. (2011). Effects of megestrol acetate on appetite and weight in patients with cancer cachexia: A systematic review. Journal of Clinical Oncology, 29(29), 3856–3863. https://doi.org/10.1200/JCO.2011.35.9525

Fearon, K., Strasser, F., Anker, S. D., et al. (2011). Definition and classification of cancer cachexia: An international consensus. The Lancet Oncology, 12(5), 489–495. https://doi.org/10.1016/S1470-2045(10)70218-7

Hui, D., Dev, R., Bruera, E. (2015). The last days of life: Symptom burden and impact on nutrition and hydration. Current Opinion in Supportive and Palliative Care, 9(4), 346–354. https://doi.org/10.1097/SPC.0000000000000177

Yavuzsen, T., Davis, M. P., Walsh, D., LeGrand, S., Lagman, R. (2005). Systematic review of the treatment of cancer-associated anorexia and weight loss. Journal of Clinical Oncology, 23(33), 8500–8511. https://doi.org/10.1200/JCO.2005.01.8010

Sheehan, J., Radparvar, S., Biewald, M. (2025) The Anorexia-Cachexia Syndrome: Pharmacologic Management. Palliative Care Network of Wisconsin #515. https://www.mypcnow.org/fast-fact/the-anorexia-cachexia-syndrome-pharmacologic-management/

‍